OTCMKTS:ADDXF Addex Therapeutics (ADDXF) Stock Forecast, Price & News $0.99 0.00 (0.00%) (As of 02/3/2023) Add Compare Share Share Today's Range$0.99▼$0.9950-Day Range$0.99▼$0.9952-Week Range$0.99▼$0.99VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesShort InterestProfileChartCompetitorsHeadlinesShort Interest About Addex Therapeutics (OTCMKTS:ADDXF) StockAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Read More ADDXF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADDXF Stock News HeadlinesSeptember 20, 2023 | markets.businessinsider.comAddex mGlu2 NAM Cognition Program Receives €4 Million GrantSeptember 4, 2023 | tmcnet.comAddex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in BrainOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.July 24, 2023 | benzinga.comAddex mGlu2PAM Demonstrates Potential in Substance Use DisorderMay 12, 2023 | benzinga.comAddex Therapeutics Q1 EPS $(0.04) Up From $(0.97) YoY, Sales $542.43K Up From $264.20K YoYMay 10, 2023 | benzinga.comAddex Announces ADX71149 Phase 2 Epilepsy Clinical Study's Independent Interim Review Committee Recommends Continuing StudyApril 5, 2023 | finanznachrichten.deAddex Therapeutics: Addex Completes $5.0 Million Equity FinancingApril 5, 2023 | benzinga.comAddex Completes $5.0 Million Equity FinancingOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.April 4, 2023 | tmcnet.comAddex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson's DiseaseMarch 30, 2023 | markets.businessinsider.comAddex Therapeutics FY22 Loss Widens, Income DownJune 17, 2022 | benzinga.comAddex Stops Parkinson's-Associated Dyskinesia Trial - Read Here WhyDecember 18, 2019 | www.globenewswire.comADDEX THERAPEUTICS PUBLICLY FILES REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSs REPRESENTING SHARESApril 30, 2019 | seekingalpha.comTrevi Therapeutics IPO: At Phase 3 Of DevelopmentSee More Headlines Receive ADDXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADDXF Company Calendar Today10/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ADDXF CUSIPN/A CIKN/A Webwww.addextherapeutics.com Phone41 22 884 1555FaxN/AEmployees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.25 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Timothy Mark Dyer (Age 54)Co-Founder, CEO & Director Dr. Roger G. Mills M.D. (Age 65)Chief Medical Officer & Director Mr. Lénaic Teyssédou (Age 36)Head of Fin. Dr. Jean-Philippe Rocher Ph.D. (Age 63)Head of Discovery - Chemistry Dr. Robert Lutjens (Age 54)Head of Discovery - Biology Dr. Mikhail Kalinichev Ph.D. (Age 54)Head of Translational Science Dr. Werner Henrichi Ph.D. (Age 79)Consultant More ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYAlseres PharmaceuticalsOTCMKTS:ALSEView All Competitors ADDXF Stock - Frequently Asked Questions How have ADDXF shares performed in 2023? Addex Therapeutics' stock was trading at $0.99 at the beginning of 2023. Since then, ADDXF stock has increased by 0.0% and is now trading at $0.99. View the best growth stocks for 2023 here. What is Addex Therapeutics' stock symbol? Addex Therapeutics trades on the OTCMKTS under the ticker symbol "ADDXF." How do I buy shares of Addex Therapeutics? Shares of ADDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Addex Therapeutics' stock price today? One share of ADDXF stock can currently be purchased for approximately $0.99. How can I contact Addex Therapeutics? The official website for the company is www.addextherapeutics.com. The company can be reached via phone at 41 22 884 1555. This page (OTCMKTS:ADDXF) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.